## Andreas Bockisch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/374969/publications.pdf Version: 2024-02-01

		394421	395702
32	2,133	19	33
papers	citations	h-index	g-index
33	33	33	2391
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Non–Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology, 2003, 229, 526-533.	7.3	525
2	PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics, 2015, 5, 1388-1401.	10.0	186
3	Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2018, 36, 2024-2034.	1.6	176
4	Optimized <sup>124</sup> I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2008, 49, 1017-1023.	5.0	135
5	Hybrid Imaging by SPECT/CT and PET/CT: Proven Outcomes in Cancer Imaging. Seminars in Nuclear Medicine, 2009, 39, 276-289.	4.6	130
6	Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. Journal of Nuclear Medicine, 2002, 43, 1339-42.	5.0	130
7	lodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 611-623.	6.4	89
8	Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 48-56.	6.4	69
9	Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. European Radiology, 2017, 27, 4091-4099.	4.5	66
10	The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2298-2306.	6.4	65
11	Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2267-2276.	6.4	61
12	Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. Journal of Nuclear Medicine, 2005, 46, 429-35.	5.0	60
13	Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 884-895.	6.4	59
14	Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1429-1439.	6.4	56
15	Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT. European Journal of Radiology, 2016, 85, 1941-1947.	2.6	50
16	High Level of Agreement Between Pretherapeutic <sup>124</sup> I PET and Intratherapeutic <sup>131</sup> I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases. Journal of Nuclear Medicine, 2016, 57, 1339-1342.	5.0	39
17	Integrated FDC PET/MR Imaging for the Assessment of Myocardial Salvage in Reperfused Acute Myocardial Infarction. Radiology, 2015, 276, 400-407.	7.3	37
18	The Xbal G>T Polymorphism of the Glucose Transporter 1 Gene Modulates 18F-FDG Uptake and Tumor Aggressiveness in Breast Cancer. Journal of Nuclear Medicine, 2010, 51, 1191-1197.	5.0	23

ANDREAS BOCKISCH

#	Article	IF	CITATIONS
19	Hybrid imaging of the bowel using PET/MR enterography: Feasibility and first results. European Journal of Radiology, 2016, 85, 414-421.	2.6	22
20	The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 235-252.	0.7	20
21	Matched pairs for radionuclide-based imaging and therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1-3.	6.4	19
22	Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging. EJNMMI Physics, 2014, 1, 100.	2.7	17
23	Prognostic value of 18F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. International Journal of Cardiovascular Imaging, 2015, 31, 1677-1685.	1.5	17
24	18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1646-1652.	6.4	16
25	Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. BMC Cancer, 2017, 17, 887.	2.6	16
26	Value of <sup>18</sup> Fâ€ <scp>FDG PET</scp> / <scp>MRI</scp> for the outcome of <scp>CT</scp> â€guided facet block therapy in cervical facet syndrome: initial results. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 327-333.	1.8	15
27	Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 301-308.	2.0	11
28	Discrepant salivary gland response after radioiodine and MIBG therapies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 331-339.	0.7	7
29	Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1988-1994.	6.4	5
30	Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1185-1186.	6.4	4
31	The effect of radioiodine therapy after total thyroidectomy. Nature Reviews Endocrinology, 2013, 9, 511-512.	9.6	2
32	Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2611-2621.	2.5	2